Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-27T22:57:02.814Z Has data issue: false hasContentIssue false
  • English
  • Français

Low-dose oral sildenafil for patients with pulmonary hypertension: a cost-effective solution in countries with limited resources

Published online by Cambridge University Press:  22 December 2006

Vladimiro L. Vida ,
Guillermo Gaitan ,
Emilio Quezada ,
Joaquin Barnoya  and
Aldo R. Castañeda
Vladimiro L. Vida
Affiliation:
Pediatric Cardiac Surgery Unit of Guatemala, Guatemala City, Guatemala, Central America
Guillermo Gaitan
Affiliation:
Pediatric Cardiac Surgery Unit of Guatemala, Guatemala City, Guatemala, Central America
Emilio Quezada
Affiliation:
Pediatric Cardiac Surgery Unit of Guatemala, Guatemala City, Guatemala, Central America
Joaquin Barnoya
Affiliation:
Pediatric Cardiac Surgery Unit of Guatemala, Guatemala City, Guatemala, Central America
Aldo R. Castañeda
Affiliation:
Pediatric Cardiac Surgery Unit of Guatemala, Guatemala City, Guatemala, Central America
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction: Pulmonary arterial hypertension, both primary and secondary, continues to pose a therapeutic problem. In this study, we evaluate the efficacy and safety of a low-dose of oral sildenafil in 10 patients with pulmonary arterial hypertension. Methods: We administered a single daily dose of 0.5 milligrams per kilogram of sildenafil for 3 months to 10 patients with pulmonary arterial hypertension. Their average age was 26.8 years. Diagnoses were primary pulmonary arterial hypertension in 3 patients, and secondary pulmonary arterial hypertension due to congenital cardiac disease in the remaining 7 patients. Outcome measures included the clinical state, the mean pulmonary arterial pressure, and the indexed pulmonary vascular resistance; the latter two assessed at the beginning and at the end of the treatment period by cardiac catheterization. We also analysed the cost of the treatment. Results: Oral treatment was well tolerated, and resulted in an improvement of the functional capacity in 9 of the 10 patients. Pulmonary arterial pressure decreased from 70 to 60 millimetres of mercury (p equal to 0.05), and indexed pulmonary vascular resistance decreased from 21.8 to 15.8 Wood units per square metre (p equal to 0.006). The mean cost per patient for 3 months on oral treatment with sildenafil was 120.99 American dollars. Conclusions: A low dose of 0.5 milligrams per kilogram per day of oral sildenafil, instead of 1 to 4 milligrams per kilogram per day, provided early clinical and haemodynamic improvements, and proved less expensive. Additional experience is now required to define more reliably the true long-term benefits of this therapy.

Keywords

Open-labelpulmonary vascular diseaseoral medication
Type
Original Article
Information
Cardiology in the Young , Volume 17 , Issue 1 , February 2007 , pp. 72 - 77
Copyright
2007 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Galie N, Manes A, Branzi A. Emerging medical therapies for pulmonary arterial hypertension. Prog Cardiovasc Dis 2002; 45: 213–224.Google Scholar
Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival inprimary pulmonary hypertension. N Engl J Med 1992; 327: 76–81.Google Scholar
Trulock EP. Lung transplantation for primary pulmonary hypertension. Clin Chest Med 2001; 22: 583–593.Google Scholar
Rubin LJ. Executive summary and introduction. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guide. Chest 2004; 126 (Suppl): 4S–10S.Google Scholar
Lee AJ, Chiao TB, Tsang MP. Sildenafil for pulmonary hypertension. Ann Pharmacother 2005; 39: 869–884.Google Scholar
Karatza AA, Bush A, Magee AG. Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension. Int J Cardiol 2005; 100: 267–273.Google Scholar
Maloney JP. Advances in the treatment of secondary pulmonary hypertension. Curr Opin Pulm Med 2003; 9: 139–143.Google Scholar
Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24: 1007–1010.Google Scholar
McLaughin VV, Hoeper MM. Pulmonary arterial hypertension: the race for the most effective treatment. Am J Respir Crit Care Med 2005; 171: 1199–1201.Google Scholar
Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104: 1218–1222.Google Scholar
Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105: 2398–2403.Google Scholar
Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066–2069.Google Scholar
Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84: E4.Google Scholar
Oliver J, Webb DJ. Sildenafil for “blue babies”. Such unlicensed drug use might be justified as last resort. BMJ 2002: 325: 1174.Google Scholar
Juliana AE, Abbad FC. Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil. Eur J Pediatr 2005; 164: 626–629.Google Scholar
Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148–2157.Google Scholar
Zolessi R. Pharmacology Perspectives. Epoprostenol (Flolan). J Pharmacy Society Wisconsin 2001; Nov–Dec: 25–29.Google Scholar
Highland KB, Strange C, Mazur J, Simpson KN. Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest 2003; 124: 2087–2092.Google Scholar
Baker SE, Hockman RH. Inhaled iloprost in pulmonary arterial hypertension. Ann Pharmacother 2005; 39: 1265–1274.Google Scholar
The pulmonary hypertension Association website. Link: http://www.phassociation.org/Learn/treatments. Accessed October 10, 2005.
Petros AJ, Turner SC, Nunn AJ. Cost implications of using inhaled nitric oxide compared with epoprostenol for pulmonary hypertension. J Pharm Technol 1995; 11: 163–166.Google Scholar
Angus DC, Clermont G, Watson RS, Linde-Zwirble WT, Clark RH, Roberts MS. Cost-effectiveness of inhaled nitric oxide in the treatment of neonatal respiratory failure in the United States. Pediatrics 2003; 112: 1351–1360.Google Scholar
Pierce CM, Peters MJ, Cohen G, Goldman AP, Petros AJ. Cost of nitric oxide is exorbitant. BMJ 2002; 325: 336.Google Scholar
Glantz S. Primer of Biostatistics, 5th edn. McGraw-Hill, United States, 2002.
Trachte AL, Lobato EB, Urdaneta F, et al. Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann Thorac Surg 2005; 79: 194–197.Google Scholar
Kataoka M, Satoh T, Manabe T, et al. Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. Circ J 2005; 69: 461–465.Google Scholar
Lepore JJ, Maroo A, Bigatello LM, et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 2005; 127: 1647–1653.Google Scholar
Agapito AF, Sousa L, Oliveira JA, Feliciano J, Cacela D, Quininha J. Eisenmenger syndrome in the adult – experience with new drugs for the treatment of pulmonary hypertension. Rev Port Cardiol 2005; 24: 421–431.Google Scholar
Chockalingam A, Gnanavelu G, Venkatesan S, et al. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol 2005; 99: 91–95.Google Scholar
Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005; 111: 3274–3280.Google Scholar
Steiner MK, Preston IR, Klinger JR, Hill NS. Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides. Curr Opin Pharmacol 2005; 5: 245–250.Google Scholar
Mikhail GW, Prasad SK, Li W, et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J 2004; 25: 431–436.Google Scholar